AU2013245917A1 - Improving resistance to skeletal muscle fatigue - Google Patents

Improving resistance to skeletal muscle fatigue Download PDF

Info

Publication number
AU2013245917A1
AU2013245917A1 AU2013245917A AU2013245917A AU2013245917A1 AU 2013245917 A1 AU2013245917 A1 AU 2013245917A1 AU 2013245917 A AU2013245917 A AU 2013245917A AU 2013245917 A AU2013245917 A AU 2013245917A AU 2013245917 A1 AU2013245917 A1 AU 2013245917A1
Authority
AU
Australia
Prior art keywords
alkyl
xii
nrdc
nrb
skeletal muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013245917A
Other languages
English (en)
Inventor
Darren HWEE
Jeffrey R. JASPER
Adam Kennedy
Fady Malik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of AU2013245917A1 publication Critical patent/AU2013245917A1/en
Assigned to CYTOKINETICS, INC. reassignment CYTOKINETICS, INC. Request for Assignment Assignors: CYTOKINETICS, INC., HWEE, Darren, JASPER, JEFFREY, KENNEDY, ADAM, MALIK, FADY
Priority to AU2018200930A priority Critical patent/AU2018200930A1/en
Priority to AU2019268177A priority patent/AU2019268177A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2013245917A 2012-04-11 2013-04-11 Improving resistance to skeletal muscle fatigue Abandoned AU2013245917A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018200930A AU2018200930A1 (en) 2012-04-11 2018-02-08 Improving resistance to skeletal muscle fatigue
AU2019268177A AU2019268177A1 (en) 2012-04-11 2019-11-22 Improving resistance to skeletal muscle fatigue

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261623003P 2012-04-11 2012-04-11
US61/623,003 2012-04-11
US201261646842P 2012-05-14 2012-05-14
US61/646,842 2012-05-14
US201261693061P 2012-08-24 2012-08-24
US61/693,061 2012-08-24
US201261735809P 2012-12-11 2012-12-11
US61/735,809 2012-12-11
PCT/US2013/036114 WO2013155262A2 (en) 2012-04-11 2013-04-11 Methods for improving resistance to skeletal muscle fatigue

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018200930A Division AU2018200930A1 (en) 2012-04-11 2018-02-08 Improving resistance to skeletal muscle fatigue

Publications (1)

Publication Number Publication Date
AU2013245917A1 true AU2013245917A1 (en) 2014-10-23

Family

ID=49328282

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013245917A Abandoned AU2013245917A1 (en) 2012-04-11 2013-04-11 Improving resistance to skeletal muscle fatigue
AU2018200930A Abandoned AU2018200930A1 (en) 2012-04-11 2018-02-08 Improving resistance to skeletal muscle fatigue
AU2019268177A Abandoned AU2019268177A1 (en) 2012-04-11 2019-11-22 Improving resistance to skeletal muscle fatigue

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018200930A Abandoned AU2018200930A1 (en) 2012-04-11 2018-02-08 Improving resistance to skeletal muscle fatigue
AU2019268177A Abandoned AU2019268177A1 (en) 2012-04-11 2019-11-22 Improving resistance to skeletal muscle fatigue

Country Status (15)

Country Link
US (2) US20150250784A1 (https=)
EP (1) EP2836590A4 (https=)
JP (2) JP6352244B2 (https=)
KR (1) KR102163931B1 (https=)
CN (2) CN111840294A (https=)
AU (3) AU2013245917A1 (https=)
BR (1) BR112014025251B1 (https=)
CA (1) CA2869675C (https=)
EA (1) EA032480B1 (https=)
HK (1) HK1206389A1 (https=)
IL (2) IL234886A (https=)
MX (1) MX2014012179A (https=)
PH (1) PH12014502286B1 (https=)
SG (2) SG11201406359TA (https=)
WO (1) WO2013155262A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
KR101951220B1 (ko) 2011-07-13 2019-02-22 싸이토키네틱스, 인코포레이티드 조합 als 치료법
EP2970240B1 (en) 2013-03-14 2018-01-10 Novartis AG 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
HUE057533T2 (hu) * 2014-04-29 2022-05-28 Cytokinetics Inc Eljárások vitálkapacitás csökkenésének gátlására
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
JP6573618B2 (ja) * 2014-09-09 2019-09-11 アステラス製薬株式会社 尿失禁予防用及び／又は治療用新規医薬組成物
BR112018016475A2 (en) 2016-02-12 2018-12-26 Cytokinetics, Incorporated tetrahydroisoquinoline derivatives
EP3484876A1 (en) 2016-07-14 2019-05-22 Pfizer Inc Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
KR20220038056A (ko) 2019-07-23 2022-03-25 아모피컬 리미티드 운동 수행능력을 개선시키기 위한 비정질 탄산칼슘
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
WO2022099011A1 (en) 2020-11-06 2022-05-12 Cytokinetics, Inc. Bicyclic 1,4-diazepanones and therapeutic uses thereof
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
IL316201A (en) 2022-04-08 2024-12-01 Eikonizo Therapeutics Inc Oxadiazole HDAC6 inhibitors and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005139081A (ja) * 2003-11-04 2005-06-02 Takada Seiyaku Kk ビントペロール含有製剤
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
CN101522681B (zh) * 2006-08-02 2012-10-03 赛特凯恩蒂克公司 特定的化学个体、组合物和方法
EP2244711A4 (en) * 2008-02-04 2011-08-24 Cytokinetics Inc CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
SG10201701101YA (en) * 2012-04-02 2017-04-27 Cytokinetics Inc Methods for improving diaphragm function

Also Published As

Publication number Publication date
BR112014025251B1 (pt) 2021-03-02
HK1206389A1 (en) 2016-01-08
PH12014502286A1 (en) 2014-12-15
JP6535727B2 (ja) 2019-06-26
JP2015516392A (ja) 2015-06-11
CA2869675C (en) 2022-06-14
JP6352244B2 (ja) 2018-07-04
MX2014012179A (es) 2015-07-14
US20190167676A1 (en) 2019-06-06
IL250473A0 (en) 2017-03-30
PH12014502286B1 (en) 2014-12-15
CA2869675A1 (en) 2013-10-17
AU2018200930A1 (en) 2018-03-01
KR102163931B1 (ko) 2020-10-12
CN104395458A (zh) 2015-03-04
KR20160046694A (ko) 2016-04-29
SG11201406359TA (en) 2014-11-27
WO2013155262A3 (en) 2013-12-27
US20150250784A1 (en) 2015-09-10
SG10201704166RA (en) 2017-06-29
AU2019268177A1 (en) 2019-12-12
EP2836590A4 (en) 2016-04-13
EA032480B1 (ru) 2019-06-28
EP2836590A2 (en) 2015-02-18
WO2013155262A2 (en) 2013-10-17
IL234886A (en) 2017-02-28
CN111840294A (zh) 2020-10-30
EA201491666A1 (ru) 2015-03-31
JP2018048209A (ja) 2018-03-29

Similar Documents

Publication Publication Date Title
US20190167676A1 (en) Methods for improving resistance to skeletal muscle fatigue
AU2017272286B2 (en) Methods for improving diaphragm function
Patil et al. Pyridine and its biological activity: a review
EP2974727A1 (en) Pharmaceutical compositions and their methods of use
JP7514534B2 (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
JP6419294B2 (ja) シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法
JP2016528266A (ja) 位相変位睡眠障害を処置するためのＶ１ａアンタゴニスト
Swedberg et al. AZD9272 and AZD2066: selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects
KR20200090198A (ko) 트로포미오신 수용체 키나제 A(TrkA) 저해제로서의 피리미딘 유도체
CN100413539C (zh) 5-ht4受体拮抗剂在制备治疗电生理心房改型的药物中的应用
EA041725B1 (ru) Применение активатора тропонина скелетных мышц

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CYTOKINETICS, INC.

Free format text: FORMER APPLICANT(S): KENNEDY, ADAM; MALIK, FADY; HWEE, DARREN; JASPER, JEFFREY; CYTOKINETICS, INC.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted